Inadequate Response to Clopidogrel Leads to Higher Incidence of Major Adverse Cardiac Events in Patients Who have Undergone PCIBy Accumetrics Inc., PRNE
Sunday, March 14, 2010
Results suggest increased need for quantifying patient response to clopidogrel through point-of-care testing
SAN DIEGO, March 15, 2010 - Accumetrics, Inc., a privately-held developer and marketer of the
VerifyNow(R) System, the first rapid and easy-to-use point-of-care system for
measuring platelet reactivity to multiple antiplatelet agents, announced the
presentation of a 2,000 patient meta-analysis examining patient response to
antiplatelet therapy after percutaneous coronary intervention (PCI). Data
from the patient-level meta-analysis show that individuals with an inadequate
response to clopidogrel have a higher incidence of major adverse cardiac
Somjot S. Brar, MD, Director of Vascular Medicine & Staff Interventional
Cardiologist at Kaiser Permanente, presented the results at the American
College of Cardiology's ACC.10 conference in Atlanta. "Our data suggest that
approximately 35% of patients undergoing PCI have poor response to
clopidogrel, which is consistent with previous findings," said Dr. Brar.
"These patients with inadequate response identified by the VerifyNow test may
have twice the risk of ischemic events or death."
The analysis showed results consistent with previous publications on the
clinical utility and importance of assessing response to antiplatelet therapy
using the VerifyNow P2Y12 platelet function test, including the recently
published POPular trial (JAMA Feb 2010).
Dr. Brar continued, "These data could not have come at a more appropriate
time based on the FDA's recent warning that genetic differences may reduce
the effectiveness of clopidogrel. Many studies, including our own, have
repeatedly shown that there are several factors, including genetics,
concomitant medications and pre-existing conditions such as diabetes, that
influence the effectiveness of clopidogrel and ultimately clinical outcomes."
Platelet function tests, such as the VerifyNow P2Y12 Test, measure the
combined effect of all of these factors.
The VerifyNow System is widely used in various clinical settings where
antiplatelet medications are prescribed to reduce the occurrence of future
thrombotic events such as heart attack and stroke.
Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic
tests for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy to use platform
to help physicians determine an individual's response to multiple
antiplatelet agents. Addressing every major antiplatelet drug, including
FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel
(Effient(R)) and clopidogrel (Plavix(R))), and GP IIb/IIIa inhibitors (e.g.
ReoPro(R) and Integrilin(R)), the VerifyNow System provides a valuable tool
to help physicians make informed treatment decisions. For more information
about the Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is
a registered trademark of sanofi-aventis. Effient is a registered trademark
of Eli Lilly and Company.
Megan Rusnack Lippert/Heilshorn & Associates +1-212-838-3777 firstname.lastname@example.org Timothy I. Still President and CEO Accumetrics +1-858-404-8260 email@example.com
Timothy I. Still, President and CEO, Accumetrics, +1-858-404-8260, press at accumetrics.com; Megan Rusnack, Lippert/Heilshorn & Associates, +1-212-838-3777, mrusnack at lhai.com
Tags: Accumetrics Inc., california, India, March 15, San diego, Western Europe